| 1 |
34031188 | TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. | 2021 Aug |
1 |
| 2 |
31119730 | Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. | 2020 Jan 15 |
1 |
| 3 |
31712394 | Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. | 2020 Feb |
1 |
| 4 |
32436611 | Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. | 2020 Jun |
4 |
| 5 |
29528476 | Evidence that Extreme Dilutions of Paclitaxel and Docetaxel Alter Gene Expression of In Vitro Breast Cancer Cells. | 2018 Feb |
1 |
| 6 |
27520484 | Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer. | 2016 Oct 15 |
1 |
| 7 |
27611952 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. | 2016 Oct 18 |
2 |
| 8 |
25385265 | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | 2015 Feb |
1 |
| 9 |
26269716 | Informative gene network for chemotherapy-induced peripheral neuropathy. | 2015 |
1 |
| 10 |
23482764 | β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells. | 2013 Mar |
1 |
| 11 |
23563592 | p53 interferes with microtubule-stabilizing agent-induced apoptosis in prostate and colorectal cancer cells. | 2013 Jun |
1 |
| 12 |
23672670 | Caspase-2 is involved in cell death induction by taxanes in breast cancer cells. | 2013 May 15 |
1 |
| 13 |
23804139 | p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. | 2013 |
1 |
| 14 |
22551440 | Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. | 2012 May 2 |
2 |
| 15 |
21570352 | TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. | 2011 Jun |
2 |
| 16 |
22075440 | Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. | 2011 Nov 10 |
1 |
| 17 |
22331725 | TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas. | 2011 Oct-Dec |
1 |
| 18 |
19150122 | Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. | 2009 Mar |
1 |
| 19 |
18230133 | TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. | 2008 Jan 29 |
5 |
| 20 |
18510179 | Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. | 2008 Mar |
2 |
| 21 |
17190831 | Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. | 2007 Feb 23 |
1 |
| 22 |
15138567 | Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. | 2004 Jun |
1 |
| 23 |
11981003 | Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. | 2002 May 1 |
1 |
| 24 |
12435289 | The European experience with docetaxel in the treatment of early-stage breast cancer. | 2002 Oct |
2 |
| 25 |
11212244 | Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. | 2001 Jan 15 |
1 |
| 26 |
11340581 | A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. | 2001 Jun 1 |
3 |